Home > Insider Trading > Filing (0001209191-14-077149)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368148	Athersys Inc / New	ATHX	Pharmaceutical Preparations (2834)	204864095

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1402610	J John Harrington	3201 Carnegie Avenue Cleveland OH 44115	Evp & Chief Scientific Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-12-17	1,106	$1.23	578,204	No	4	F	Direct
Common Stock	Disposition	2014-12-18	15,619	$1.29	562,585	No	4	F	Direct
Common Stock	Disposition	2014-12-18	4,100	$1.30	558,485	No	4	S	Direct
Common Stock	Disposition	2014-12-19	4,050	$1.28	554,435	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Shares withheld from the quarterly vesting of a June 2014 restricted stock unit award related to the minimum tax withholding obligation.
Shares withheld from the quarterly vesting of a June 2013 restricted stock unit award related to the minimum tax withholding obligation.
Shares sold pursuant to a predefined Rule 10b5-1 trading plan solely related to the tax obligation on the quarterly vesting of a June 2013 restricted stock unit award.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.16 to $1.40, inclusive, in accordance with a previously established Rule 10b5-1 predefined trading plan enacted solely related to the tax obligation.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.24 to $1.33, inclusive, in accordance with a previously established Rule 10b5-1 predefined trading plan enacted solely related to the tax obligation.
Securities beneficially owned are comprised of: (1) 222,036 shares of common stock owned, (2) unvested 285,275 restricted stock units awarded in June 2013 related to the termination of 2005 incentive agreements that will vest ratably on a quarterly basis through June 18, 2016, and (3) unvested restricted stock units awarded on an annual basis amounting to 47,124 that vest quarterly over a four-year period from grant date.